Advertisement

Minimal Residual Disease in Melanoma

Biology, Detection and Clinical Relevance

  • Uwe Reinhold
  • Wolfgang Tilgen

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 158)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Biology of Micrometastases and Advances in Methods for Detection

    1. Front Matter
      Pages 1-1
    2. R. L. Barnhil
      Pages 3-13
    3. N. Max, K. Wolf, B. Spike, E. Thiel, U. Keilholz
      Pages 25-31
    4. Ø. Fodstad, R. Faye, H. K. Høifødt, E. Skovlund, S. Aamdal
      Pages 40-50
  3. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow

  4. Detection of Minimal Residual Disease in Sentinel Nodes

    1. Front Matter
      Pages 127-127
    2. D. Bachter, C. Michl, H. Büchels, H. Vogt, B. R. Balda
      Pages 129-136
    3. H.-J. Blaheta, B. Schittek, H. Breuninger, C. Garbe
      Pages 137-146
  5. Early Recognition and Monitoring by Serological Markers

    1. Front Matter
      Pages 147-147
    2. J. M. G. Bonfrer, C. M. Korse
      Pages 149-157
    3. A. K. Bosserhoff, D. Dreau, R. Hein, M. Landthaler, W. D. Holder, R. Buettner
      Pages 158-168
    4. A. Hauschild, R. Gläser, E. Christophers
      Pages 169-177
  6. Clinical Relevance of Micrometastases Detection

    1. Front Matter
      Pages 179-179
    2. M. von Knebel Doeberitz, J. Weitz, M. Koch, J. Lacroix, A. Schrödel, C. Herfarth
      Pages 181-186
    3. S. C. Shivers, W. Li, J. Lin, A. Stall, M. Stafford, J. Messina et al.
      Pages 187-199
    4. G. Palmieri, M. Pirastu, M. Strazzullo, P. A. Ascierto, S. M. R. Satriano, M. L. Motti et al.
      Pages 200-203
    5. J.-C. Bystryn, J. Albrecht, S. R. Reynolds, M. C. Rivas, R. Oratz, R. L. Shapiro et al.
      Pages 204-207
  7. Therapeutic Strategies Against Residual Melanoma Cells

  8. Back Matter
    Pages 265-268

About these proceedings

Introduction

Knowledge about diagnostic procedures in melanoma has in­ creased rapidly within the past few years. Single tumor cells have been identified in normal tissue such as sentinel lymph nodes, as well as in bone marrow, peripheral blood, and other bodily fluids and cells, by molecular technologies. The introduction of polymerase chain reaction-based methods can be regarded as a prototype of this dramatic development towards molecular approaches in new diagnostic procedures. This fact opens up the possibility of clinical use in patients and of influencing treatment strategies. Considerable discrepancies have been described, how­ ever, in the success rates of these new techniques for the detec­ tion of minimal residual disease in cancer patients. Despite fav­ orable results reported by different groups of investigators, it will take several years to define the clinical and pathophysiological relevance of new diagnostic procedures. The 1st International Symposium "Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance of Microme­ tastases", held in September 1999 in Homburg/Saar, Germany, fo­ cused on recent developments in this particular area of cancer re­ search. The purpose of the meeting was to stimulate discussion and exchange of new data and ideas by renowned international scientists. The aim of this volume is to summarize major topics of basic research and clinical investigations presented by invited experts in this fascinating but still. controversial field of melanoma re­ search.

Keywords

Staging Tumormarker diagnostics metastatic disease sentinel node therapy tissue tumor marker

Editors and affiliations

  • Uwe Reinhold
    • 1
  • Wolfgang Tilgen
    • 1
  1. 1.Universitätskliniken des Saarlandes Haut- und PoliklinikHomburg/SaarGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-59537-0
  • Copyright Information Springer-Verlag Berlin Heidelberg 2001
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-64015-5
  • Online ISBN 978-3-642-59537-0
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Biomedicine
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology